FI942075L - Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina - Google Patents
Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina Download PDFInfo
- Publication number
- FI942075L FI942075L FI942075A FI942075A FI942075L FI 942075 L FI942075 L FI 942075L FI 942075 A FI942075 A FI 942075A FI 942075 A FI942075 A FI 942075A FI 942075 L FI942075 L FI 942075L
- Authority
- FI
- Finland
- Prior art keywords
- derivatives
- pharmaceuticals
- compounds
- preparation
- bile acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4315368 | 1993-05-08 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI942075A0 FI942075A0 (fi) | 1994-05-05 |
| FI942075A7 FI942075A7 (fi) | 1994-11-09 |
| FI942075L true FI942075L (fi) | 1994-11-09 |
Family
ID=6487579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI942075A FI942075L (fi) | 1993-05-08 | 1994-05-05 | Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5466815A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0624596B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP3476157B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100333149B1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE163938T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU666440B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2123048C (cg-RX-API-DMAC7.html) |
| CY (1) | CY2119B1 (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ289515B6 (cg-RX-API-DMAC7.html) |
| DE (1) | DE59405410D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0624596T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2115096T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI942075L (cg-RX-API-DMAC7.html) |
| GR (1) | GR3026496T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HU217439B (cg-RX-API-DMAC7.html) |
| IL (1) | IL109581A (cg-RX-API-DMAC7.html) |
| NO (1) | NO304795B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ260469A (cg-RX-API-DMAC7.html) |
| TW (1) | TW289757B (cg-RX-API-DMAC7.html) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW289020B (cg-RX-API-DMAC7.html) * | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| EP0624593A3 (de) * | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| US6323190B1 (en) * | 1998-07-31 | 2001-11-27 | The Univeristy Of Georgia Research Foundation, Inc. | Estrogen mimetics lacking reproductive tract effects |
| WO2000066611A1 (en) | 1999-04-30 | 2000-11-09 | Arch Development Corporation | Steroid derivatives |
| US7086134B2 (en) * | 2000-08-07 | 2006-08-08 | Shipley Company, L.L.C. | Alignment apparatus and method for aligning stacked devices |
| CA2438221A1 (en) * | 2001-02-08 | 2002-08-15 | The University Of Chicago | Steroidal derivatives |
| US20070197484A1 (en) * | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| CA2446314C (en) * | 2001-05-03 | 2011-02-22 | The University Of Chicago | Liver x receptor agonists |
| US7078396B2 (en) * | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
| US6816317B2 (en) * | 2002-01-31 | 2004-11-09 | Lightel Technologies Inc. | Collimator for ready fitting to an optical device with precise optical alignment without need for adjusting positions or angles to compensate for offsets or deviations during optical device assembly and method of making same |
| WO2003086303A2 (en) * | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| ES2564167T3 (es) * | 2004-07-08 | 2016-03-18 | Novo Nordisk A/S | Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol |
| US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| US7960439B1 (en) | 2006-06-12 | 2011-06-14 | Iowa State University Research Foundation, Inc. | Environmentally sensitive foldable oligomers |
| US8829213B2 (en) * | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| LT3023102T (lt) | 2010-11-04 | 2018-09-25 | Albireo Ab | Ibat inhibitoriai, skirti kepenų ligų gydymui |
| CA2815698C (en) | 2010-11-08 | 2019-04-30 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| KR20170094184A (ko) | 2014-11-06 | 2017-08-17 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| KR20170099909A (ko) * | 2014-11-26 | 2017-09-01 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| SG11201706089RA (en) * | 2015-02-11 | 2017-09-28 | Enanta Pharm Inc | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| PT3277286T (pt) | 2015-03-31 | 2021-07-01 | Enanta Pharm Inc | Derivados de ácidos biliares como agonistas de fxr/tgr5 e métodos de utilização destes |
| CN107250150B (zh) * | 2015-04-28 | 2019-11-22 | 江苏豪森药业集团有限公司 | 胆酸衍生物及其制备方法和医药用途 |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN108601744B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| WO2018102418A1 (en) | 2016-11-29 | 2018-06-07 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| WO2018187804A1 (en) | 2017-04-07 | 2018-10-11 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| PL3810581T3 (pl) | 2018-06-20 | 2025-04-28 | Albireo Ab | Modyfikacje kryształu odewiksibatu |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| TW202043204A (zh) * | 2019-01-14 | 2020-12-01 | 中國大陸商北京軒義醫藥科技有限公司 | 四唑啉酮取代的類固醇化合物及其用途 |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| SMT202300020T1 (it) | 2019-02-06 | 2023-03-17 | Albireo Ab | Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari |
| CA3127408A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2020190358A1 (en) * | 2019-03-19 | 2020-09-24 | Siemens Healthcare Diagnostics Inc. | Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CR20220315A (es) | 2019-12-04 | 2022-10-26 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| EP4511038A1 (en) | 2022-04-22 | 2025-02-26 | Albireo AB | Subcutaneous administration of an asbt inhibitor |
| EP4538280A1 (en) * | 2022-06-09 | 2025-04-16 | Shandong Luye Pharmaceutical Co., Ltd. | 19-nor-c3,3-disubstituted c21-azacyclo-substituted steroid and method for using same |
| JP2025524362A (ja) | 2022-06-09 | 2025-07-30 | アルビレオ・アクチボラグ | 肝炎の処置 |
| AU2023304672A1 (en) | 2022-07-05 | 2025-01-02 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4629997A1 (en) | 2022-12-09 | 2025-10-15 | Albireo AB | Asbt inhibitors in the treatment of renal diseases |
| WO2025119319A1 (zh) * | 2023-12-08 | 2025-06-12 | 山东绿叶制药有限公司 | 一种gabaa受体调节剂的晶型及其制备方法和应用 |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| DE59108326D1 (de) * | 1990-12-06 | 1996-12-12 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel |
-
1993
- 1993-11-23 TW TW082109825A patent/TW289757B/zh active
-
1994
- 1994-05-02 AT AT94106848T patent/ATE163938T1/de not_active IP Right Cessation
- 1994-05-02 DE DE59405410T patent/DE59405410D1/de not_active Expired - Lifetime
- 1994-05-02 ES ES94106848T patent/ES2115096T3/es not_active Expired - Lifetime
- 1994-05-02 DK DK94106848T patent/DK0624596T3/da active
- 1994-05-02 EP EP94106848A patent/EP0624596B1/de not_active Expired - Lifetime
- 1994-05-05 FI FI942075A patent/FI942075L/fi unknown
- 1994-05-05 US US08/238,741 patent/US5466815A/en not_active Expired - Lifetime
- 1994-05-06 CZ CZ19941135A patent/CZ289515B6/cs not_active IP Right Cessation
- 1994-05-06 JP JP09442494A patent/JP3476157B2/ja not_active Expired - Fee Related
- 1994-05-06 HU HU9401443A patent/HU217439B/hu not_active IP Right Cessation
- 1994-05-06 NZ NZ260469A patent/NZ260469A/en unknown
- 1994-05-06 CA CA002123048A patent/CA2123048C/en not_active Expired - Fee Related
- 1994-05-06 IL IL109581A patent/IL109581A/en not_active IP Right Cessation
- 1994-05-06 NO NO934800A patent/NO304795B1/no not_active IP Right Cessation
- 1994-05-06 AU AU61947/94A patent/AU666440B2/en not_active Ceased
- 1994-05-07 KR KR1019940009971A patent/KR100333149B1/ko not_active Expired - Fee Related
-
1998
- 1998-04-03 GR GR980400679T patent/GR3026496T3/el unknown
- 1998-09-29 CY CY9800037A patent/CY2119B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU666440B2 (en) | 1996-02-08 |
| HUT67390A (en) | 1995-04-28 |
| CA2123048A1 (en) | 1994-11-09 |
| DE59405410D1 (de) | 1998-04-16 |
| CA2123048C (en) | 2005-11-29 |
| FI942075A0 (fi) | 1994-05-05 |
| EP0624596A2 (de) | 1994-11-17 |
| CY2119B1 (en) | 2002-04-26 |
| ES2115096T3 (es) | 1998-06-16 |
| HU9401443D0 (en) | 1994-08-29 |
| TW289757B (cg-RX-API-DMAC7.html) | 1996-11-01 |
| GR3026496T3 (en) | 1998-07-31 |
| JPH06329695A (ja) | 1994-11-29 |
| DK0624596T3 (da) | 1998-10-07 |
| ATE163938T1 (de) | 1998-03-15 |
| IL109581A0 (en) | 1994-08-26 |
| CZ289515B6 (cs) | 2002-02-13 |
| AU6194794A (en) | 1994-11-10 |
| NO941677D0 (no) | 1994-05-06 |
| IL109581A (en) | 1998-03-10 |
| HU217439B (hu) | 2000-01-28 |
| EP0624596B1 (de) | 1998-03-11 |
| JP3476157B2 (ja) | 2003-12-10 |
| NZ260469A (en) | 1995-03-28 |
| KR100333149B1 (ko) | 2002-09-19 |
| CZ113594A3 (en) | 1994-12-15 |
| US5466815A (en) | 1995-11-14 |
| FI942075A7 (fi) | 1994-11-09 |
| EP0624596A3 (de) | 1995-06-07 |
| NO304795B1 (no) | 1999-02-15 |
| NO941677L (no) | 1994-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI942075A7 (fi) | Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina | |
| FI942076A7 (fi) | Sappihappojohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkaaineina | |
| FI942077A7 (fi) | Monomeerisiä sappihappojohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina | |
| FI942074A7 (fi) | nor-sappijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina | |
| FI953467A7 (fi) | Aminohappojohdannaisia, näitä yhdisteitä sisältävät lääkeaineet ja men etelmä niiden valmistamiseksi | |
| FI935513A7 (fi) | Karboksyylihappojohdannaiset, näitä sistältävät lääkeaineet ja menetelmä niiden valmistamiseksi | |
| FI941987A7 (fi) | Uudet aminohappojohdannaiset, menetelmät niiden valmistamiseksi ja näi tä yhdisteitä sisältävät farmaseuttiset koostumukset | |
| FI964473A7 (fi) | Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näit ä yhdisteitä sisältävät farmaseuttiset koostumukset (II) | |
| FI973148A7 (fi) | Substituoituja heterosyklisiä yhdisteitä, menetelmä niiden valmistamis eksi ja niitä sisältäviä farmaseuttisia koostumuksia | |
| FI943687L (fi) | Uudet 11-bentsaldoksiimiestradieenijohdannaiset, menetelmät niiden valmistamiseksi ja näitä yhdisteitä sisältävät lääkeaineet | |
| FI935360L (fi) | Guanidiinialkyyli-1,1-bifosfonihappojohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö | |
| IL131751A0 (en) | Aryl-or heteroarylsulfonamide substituted hydroxamic acid derivatives process for their preparation and their use as pharmaceuticals | |
| FI945776L (fi) | Yhden astian menetelmä 3-kinolonikarboksyylihaapojohdannaisten valmistamiseksi | |
| FI951387L (fi) | Sulfonamidokarbonyylipyridiini-2-karboksyylihappoesteriamidit sekä niiden pyridiini-N-oksidit, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä | |
| EE9500059A (et) | Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena | |
| FI925734A7 (fi) | Polyaspartamidijohdoksia sappihapon adsorptioaineina, sappihappoja sisältäviä polyaspartamidijohdoksia ja menetelmä niiden valmistamiseksi sekä niiden käyttö lääkkeinä | |
| FI931332A0 (fi) | Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi | |
| FI963885L (fi) | Pyrimidiini- tai triatsiinikarboksyylihappojohdannaiset käytettäväksi lääkaineina | |
| FI956278A0 (fi) | Substituoituja 4-fenyylitiatsolijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia | |
| EE9600023A (et) | Fenüültsükloheksüülkarboksüülhappeamiidid, nende valmistamismeetod, kasutamine ravimite valmistamiseks, nimetatud ühendeid sisaldavad ravimid ja nende valmistamismeetod | |
| FI963440A7 (fi) | Uudet aminohappojohdannaiset, näiden valmistusmenetelmä ja näitä yhdis teitä sisältävät farmaseuttiset seokset | |
| FI931599A7 (fi) | Bentsimidatsolit, näitä yhdisteitä sisältävät lääkeaineet ja menetelmäniiden valmistamiseksi | |
| FI930236A7 (fi) | Bentsimidatsolit, näitä yhdisteitä sisältävät lääkeaineet ja menetelmäniiden valmistamiseksi | |
| FI941094L (fi) | Uudet erytromysiinijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä | |
| EE03803B1 (et) | a-amino- ja tsüklopentaan-ß-aminohapet(-happeid) ja/või nende derivaate sisaldavad segud ja dipeptiidid, dipeptiidide valmistamismeetod ning nimetatud segusid ja/või dipeptiide sisaldavad ravimid |